2023 World Conference on Lung Cancer (Posters)-EP13.07. A Study of Sintilimab Combined with Anlotinib and chemotherapy as Second-Line or Later Therapy in Extensive-Disease Small Cell Lung Cancer

EP13.07. A Study of Sintilimab Combined with Anlotinib and chemotherapy as Second-Line or Later Therapy in Extensive-Disease Small Cell Lung Cancer - PDF(Abstract)

Back to course

Pdf Summary

This study investigated the efficacy and safety of a treatment regimen consisting of sintilimab, anlotinib, and albumin-bound paclitaxel as second-line or later therapy for patients with extensive-disease small cell lung cancer (ED-SCLC). ED-SCLC is a type of lung cancer characterized by rapid growth, drug resistance, and early metastasis. Currently, the standard first-line treatment for ED-SCLC is etoposide combined with platinum, but options for second-line and later treatments are limited.<br /><br />The study enrolled 30 patients who had failed one or more lines of previous treatment. They were treated with sintilimab, anlotinib, and albumin-bound paclitaxel for 4-6 cycles. After that, patients without disease progression continued to receive sintilimab alone. The primary endpoint of the study was the objective response rate (ORR), and secondary endpoints included disease control rate (DCR), duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety.<br /><br />The results showed that out of the 23 patients evaluated, the ORR was 60.9% and the DCR was 73.9%. The median PFS was 5.91 months, and the 6-month PFS rate was 48.6%. The median OS was 13.2 months, with 12- and 18-month OS rates of 58.8% and 46.3% respectively. The median DOR was 6.8 months, and the median time to response was 1.5 months.<br /><br />The overall safety of the treatment regimen was manageable, with most adverse events being grade 1-2. Only 21.7% of patients experienced grade 3 adverse events, including hypertriglyceridemia, increased aspartate aminotransferase, increased alanine aminotransferase, rash, neutropenia, and lymphopenia.<br /><br />In conclusion, the combination treatment of sintilimab, anlotinib, and albumin-bound paclitaxel showed significant clinical activity and a manageable safety profile as a second-line or later therapy for patients with ED-SCLC. The long-term efficacy of this treatment regimen is still being followed up.

Asset Subtitle

Zhehai Wang

Meta Tag

Speaker Zhehai Wang

Topic SCLC & Neuroendocrine Tumors: Relapse & Salvage Therapy

Keywords

efficacy

safety

treatment regimen

sintilimab

anlotinib

albumin-bound paclitaxel

extensive-disease small cell lung cancer

objective response rate

progression-free survival

adverse events